Compare Sana Biotechnology Inc (SANA) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Vanguard Total International Stock Index Fund ETF — how do they compare? Sana Biotechnology Inc trades at $3.76 (market cap $1.13B), while Vanguard Total International Stock Index Fund ETF trades at $87.51. The key difference: Vanguard Total International Stock Index Fund ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| SANA | VXUS | |
|---|---|---|
Market Cap | $1.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $5.92 | $87.21 |
52-Week Low | $2.68 | $70.87 |
Enterprise Value | $1.05B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
VXUS trades at $87.49, up 0.76% today, with a bullish technical signal from moving averages but overbought RSI readings. The ETF offers broad international diversification, holding over 8,700 stocks, and recently delivered a 27.82% total return over the past year. Recent news highlights institutional buying and its role in portfolio diversification.
Outlook is positive due to valuation discounts versus U.S. equities and strong inflows, but risks include global economic sensitivity and inflation pressures. Analyst sentiment is mixed, with some recommending buys for long-term holdings while others caution on near-term growth-inflation dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →
